Open AccessEfficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
Author(s) -
Kevin J. Harrington,
Andtbacka RHI,
Frances A. Collichio,
Gerald Downey,
Ling Chen,
Z. Szabó,
Herbert E. Kaufman
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/s2fs-d380
Subject(s) - medicine , granulocyte macrophage colony stimulating factor , melanoma , oncolytic virus , granulocyte colony stimulating factor , stage (stratigraphy) , cancer research , oncology , cytokine , cancer , chemotherapy , biology , paleontology